Found: 51
Select item for more details and to access through your institution.
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1758, doi. 10.1111/dom.15033
- By:
- Publication type:
- Article
Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 198, doi. 10.1111/dom.14864
- By:
- Publication type:
- Article
Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 115, doi. 10.1111/dom.14557
- By:
- Publication type:
- Article
Effect of immediate and prolonged GLP‐1 receptor agonist administration on uric acid and kidney clearance: <italic>Post‐hoc</italic> analyses of four clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1235, doi. 10.1111/dom.13223
- By:
- Publication type:
- Article
Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1669, doi. 10.1111/dom.12985
- By:
- Publication type:
- Article
Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 9, p. 1205, doi. 10.1111/dom.12935
- By:
- Publication type:
- Article
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 12, p. 1217, doi. 10.1111/dom.12748
- By:
- Publication type:
- Article
Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0188475
- By:
- Publication type:
- Article
Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury.
- Published in:
- Intensive Care Medicine Experimental, 2024, v. 12, n. 1, p. 1, doi. 10.1186/s40635-024-00647-2
- By:
- Publication type:
- Article
Tubular injury in diabetic ketoacidosis: Results from the diabetic kidney alarm study.
- Published in:
- Pediatric Diabetes, 2021, v. 22, n. 7, p. 1031, doi. 10.1111/pedi.13259
- By:
- Publication type:
- Article
306-OR: A Metabolic Mismatch between Renal Oxygenation and Glomerular Filtration Rate in Type 1 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-306-OR
- By:
- Publication type:
- Article
1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1196-P
- By:
- Publication type:
- Article
250-OR: Beta-Cell Rest Induced by Dapagliflozin Improves ß-Cell Secretory Capacity in Type 2 Diabetes Patients: A Randomized Controlled Trial vs. Gliclazide.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-250-OR
- By:
- Publication type:
- Article
243-OR: ADA Presidents' Select Abstract: Dapagliflozin Reduces Measured GFR by Reducing Renal Efferent Arteriolar Resistance in Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-243-OR
- By:
- Publication type:
- Article
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01492-x
- By:
- Publication type:
- Article
Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
- Published in:
- European Journal of Endocrinology, 2024, v. 190, n. 5, p. 391, doi. 10.1093/ejendo/lvae043
- By:
- Publication type:
- Article
Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
- Published in:
- European Journal of Endocrinology, 2017, v. 176, n. 1, p. 77, doi. 10.1530/EJE-16-0507
- By:
- Publication type:
- Article
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
- Published in:
- European Journal of Endocrinology, 2014, v. 170, n. 3, p. 429, doi. 10.1530/EJE-13-0610
- By:
- Publication type:
- Article
Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, p. i24, doi. 10.1093/ndt/gfz228
- By:
- Publication type:
- Article
Corrigendum: Safety of Semaglutide.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Fecal microbiota transplantation does not alter bacterial translocation and visceral adipose tissue inflammation in individuals with obesity.
- Published in:
- Obesity Science & Practice, 2022, v. 8, n. 1, p. 56, doi. 10.1002/osp4.545
- By:
- Publication type:
- Article
Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study.
- Published in:
- Microcirculation, 2021, v. 28, n. 6, p. 1, doi. 10.1111/micc.12700
- By:
- Publication type:
- Article
Assessment of real‐time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast‐enhanced ultrasonography vs para‐aminohippuric acid clearance.
- Published in:
- Microcirculation, 2019, v. 26, n. 7, p. N.PAG, doi. 10.1111/micc.12580
- By:
- Publication type:
- Article
The gut microbiome is associated with residual β-cell function and glycemic control in type 1 diabetes.
- Published in:
- Nederlands Tijdschrift voor Diabetologie (NTvD), 2023, v. 21, n. 4, p. 46
- By:
- Publication type:
- Article
Incretin-based drugs and renoprotection-is hyperfiltration key?
- Published in:
- Kidney International, 2015, v. 87, n. 3, p. 660, doi. 10.1038/ki.2014.398
- By:
- Publication type:
- Article
ACE-I vs. ARB for blood pressure control in diabetic kidney disease.
- Published in:
- Kidney International, 2014, v. 86, n. 6, p. 1270, doi. 10.1038/ki.2014.262
- By:
- Publication type:
- Article
Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial.
- Published in:
- BMC Psychiatry, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12888-015-0543-5
- By:
- Publication type:
- Article
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
- Published in:
- Journal of Nephrology (JNonline), 2020, v. 33, n. 5, p. 965, doi. 10.1007/s40620-020-00738-9
- By:
- Publication type:
- Article
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.
- Published in:
- Endocrine Reviews, 2021, v. 42, n. 5, p. 528, doi. 10.1210/endrev/bnab021
- By:
- Publication type:
- Article
Pancreatic <sup>18</sup>F-FDG uptake is increased in type 2 diabetes patients compared to non-diabetic controls.
- Published in:
- PLoS ONE, 2019, v. 14, n. 3, p. 1, doi. 10.1371/journal.pone.0213202
- By:
- Publication type:
- Article
Safety of Semaglutide.
- Published in:
- Frontiers in Endocrinology, 2021, v. 12, p. 1, doi. 10.3389/fendo.2021.645563
- By:
- Publication type:
- Article
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
- Published in:
- Cardiovascular Research, 2020, v. 116, n. 5, p. 916, doi. 10.1093/cvr/cvz323
- By:
- Publication type:
- Article
Residual β-Cell Function Is Associated With Longer Time in Range in Individuals With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2024, v. 47, n. 7, p. 1114, doi. 10.2337/dc23-0776
- By:
- Publication type:
- Article
Age Ain't Nothing But a Number... or Is It?
- Published in:
- Diabetes Care, 2023, v. 46, n. 6, p. 1135, doi. 10.2337/dci23-0013
- By:
- Publication type:
- Article
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Differences in Body Composition Convey a Similar Risk of Type 2 Diabetes Among Different Ethnic Groups With Disparate Cardiometabolic Risk-The HELIUS Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function.
- Published in:
- Diabetes Care, 2020, v. 43, n. 1, p. 228, doi. 10.2337/dc19-1651
- By:
- Publication type:
- Article
Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556.
- Published in:
- 2019
- By:
- Publication type:
- Journal Article
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2019, v. 42, n. 10, p. 1921, doi. 10.2337/dc19-0937
- By:
- Publication type:
- Article
The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α<sup>1-67</sup> in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.
- Published in:
- 2017
- By:
- Publication type:
- letter
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.
- Published in:
- 2016
- By:
- Publication type:
- letter
Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
- Published in:
- 2015
- By:
- Publication type:
- letter
Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.
- Published in:
- 2011
- By:
- Publication type:
- journal article